| 2026-09-03 | New trial registered | tirzepatide | · ELI LILLY AND CO | | |
| 2026-09-03 | New trial registered | tirzepatide | · ELI LILLY AND CO | | |
| 2026-09-03 | field_changed | tirzepatide | · | | |
| 2026-09-03 | field_changed | tirzepatide | · | | |
| 2026-09-03 | field_changed | tirzepatide | · | | |
| 2026-09-03 | field_changed | tirzepatide | · | | |
| 2026-09-03 | Enrollment changed | semaglutide | Bariatric Surgery vs. Semaglutide vs. Tirzepatide | 125 → 140 participants | P4 |
| 2026-09-03 | New trial registered | semaglutide | Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus | Recruiting, n=240 | P2 |
| 2026-09-02 | Results date moved | semaglutide | Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes | 2027-09-20 → 2026-01-20 20 mo earlier | P2 |
| 2026-09-02 | Status changed | semaglutide | Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes | Recruiting → Completed | P2 |
| 2026-09-02 | Enrollment changed | semaglutide | Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes | 105 → 114 participants | P2 |
| 2026-09-02 | Status changed | semaglutide | Effect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction | Not yet recruiting → Unknown | P4 |
| 2026-09-01 | New trial registered | semaglutide | Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes | Not yet recruiting, n=226 | P2/P3 |
| 2026-09-01 | Results date moved | semaglutide | A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation | 2026-05-06 → 2026-06-16 1 mo later | P2 |
| 2026-09-01 | New trial registered | tirzepatide | A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin | Not yet recruiting, n=240 | P2 |
| 2026-08-31 | New trial registered | orforglipron | A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity | Not yet recruiting, n=2,001 | P3 |
| 2026-08-31 | New trial registered | pemvidutide | Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH | Recruiting, n=1,800 | P3 |
| 2026-08-31 | Status changed | semaglutide | Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth: A Randomized Clinical Trial | Not yet recruiting → Recruiting | P3 |
| 2026-08-31 | Status changed | liraglutide | A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes | Not yet recruiting → Unknown | P3 |
| 2026-08-31 | Status changed | mazdutide | A Study of IBI362 9 mg in Chinese Adults With Obesity | Active, not recruiting → Unknown | P3 |
| 2026-08-31 | Status changed | ecnoglutide | A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA) | Not yet recruiting → Recruiting | P3 |
| 2026-08-28 | field_changed lead | liraglutide | · | | |
| 2026-08-28 | Status changed lead | liraglutide | · | Current → To Be Discontinued | |
| 2026-08-28 | field_changed lead | liraglutide | · | | |
| 2026-08-28 | Status changed | liraglutide | · | To Be Discontinued → Current | |
| 2026-08-28 | field_changed | liraglutide | · | | |
| 2026-08-28 | Results date moved | semaglutide | GLP-1R Agonist Treatment for Opioid Use Disorder | 2027-04 → 2027-04-30 | P2 |
| 2026-08-28 | Status changed | tirzepatide | Tirzepatide in Idiopathic Intracranial Hypertension Trial | Not yet recruiting → Recruiting | P4 |
| 2026-08-28 | Results date moved | mazdutide | Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or ObesityNCT07657676 · China National Center for Cardiovascular Diseases | 2027-10-31 → 2027-12-31 2 mo later | P4 |
| 2026-08-27 | New trial registered lead | tirzepatide | · ELI LILLY AND CO | | |
| 2026-08-27 | New trial registered lead | tirzepatide | · ELI LILLY AND CO | | |
| 2026-08-27 | New trial registered | semaglutide | · NOVO | | |
| 2026-08-27 | Status changed | tirzepatide | GLP-1R Actions on Muscle and the Skeleton | Active, not recruiting → Recruiting | P4 |
| 2026-08-27 | New trial registered | orforglipron | A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems | Not yet recruiting, n=192 | P3 |
| 2026-08-26 | New trial registered lead | tirzepatide | · ELI LILLY AND CO | | |
| 2026-08-26 | Results date moved | tirzepatide | A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer | 2028-12-31 → 2029-10-31 10 mo later | P2 |
| 2026-08-25 | Status changed lead | liraglutide | · | Current → To Be Discontinued | |
| 2026-08-25 | field_changed lead | liraglutide | · | | |
| 2026-08-25 | field_changed lead | liraglutide | · | | |
| 2026-08-25 | field_changed lead | liraglutide | · | | |
| 2026-08-25 | New trial registered | semaglutide | A Randomized Controlled Study of Dose-tapering Regimen of Semaglutide for Weight-Loss Maintenance in Adults With Overweight or ObesityNCT07783854 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting, n=72 | P4 |
| 2026-08-24 | Status changed | tirzepatide | Incretin Therapies in Obesity-related HFpEF | Not yet recruiting → Recruiting | P4 |
| 2026-08-24 | New trial registered | mazdutide | Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer | Not yet recruiting, n=128 | P2 |
| 2026-08-24 | Status changed | maridebart cafraglutide | Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) | Not yet recruiting → Recruiting | P3 |
| 2026-08-21 | New trial registered | lixisenatide | iGlarLixi vs IDegAsp in Chinese Participants After OAD(s) | Completed, n=582 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes | Completed, n=736 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM | Completed, n=1,170 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) | Completed, n=6,068 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs | Completed, n=513 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin | Completed, n=680 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients | Completed, n=894 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s) | Completed, n=878 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea | Completed, n=859 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan | Completed, n=521 | P3 |
| 2026-08-21 | New trial registered | aleniglipron | A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)NCT07654374 · Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Recruiting, n=1,100 | P3 |
| 2026-08-21 | New trial registered | aleniglipron | Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)NCT07654361 · Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Recruiting, n=3,600 | P3 |
| 2026-08-21 | New trial registered | albiglutide | A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes | Completed, n=685 | P3 |
| 2026-08-21 | New trial registered | albiglutide | A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine | Completed, n=586 | P3 |
| 2026-08-21 | New trial registered | albiglutide | A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment. | Completed, n=507 | P3 |
| 2026-08-21 | New trial registered | albiglutide | A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes | Completed, n=779 | P3 |
| 2026-08-21 | New trial registered | albiglutide | Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus | Completed, n=814 | P3 |
| 2026-08-21 | New trial registered | albiglutide | Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes | Completed, n=1,049 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Lixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 Diabetes | Completed, n=8 | P4 |
| 2026-08-21 | New trial registered | lixisenatide | Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | Not yet recruiting, n=324 | P4 |
| 2026-08-21 | New trial registered | lixisenatide | Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes | Completed, n=294 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin | Completed, n=426 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients | Completed, n=350 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan | Completed, n=321 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents | Terminated, n=241 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes | Enrolling by invitation, n=100 | P4 |
| 2026-08-21 | New trial registered | lixisenatide | Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric EmptyingNCT01910194 · Profil Institut für Stoffwechselforschung GmbH | Completed, n=39 | P2 |
| 2026-08-21 | New trial registered | lixisenatide | Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM) | Completed, n=265 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | The Effect of Lixisenatide on the Effect of Pituitary Hormones | Unknown, n=10 | P4 |
| 2026-08-21 | New trial registered | lixisenatide | GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin | Completed, n=496 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease | Completed, n=156 | P2 |
| 2026-08-21 | New trial registered | lixisenatide | GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS) | Completed, n=69 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians | Completed, n=119 | P4 |
| 2026-08-21 | New trial registered | lixisenatide | Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog | Terminated, n=2 | P4 |
| 2026-08-21 | New trial registered | lixisenatide | Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes | Completed, n=361 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan | Completed, n=184 | P4 |
| 2026-08-21 | New trial registered | lixisenatide | GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone | Completed, n=484 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Study on Lixisenatide and Counterregulation to Hypoglycemia | Completed, n=18 | P4 |
| 2026-08-21 | New trial registered | lixisenatide | GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy | Completed, n=361 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Effects of Insulin Glargine and Lixisenatide on the Brain | Terminated, n=1 | P4 |
| 2026-08-21 | New trial registered | lixisenatide | Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India) | Completed, n=247 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin | Completed, n=391 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years | Completed, n=319 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine | Completed, n=446 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus | Completed, n=124 | P4 |
| 2026-08-21 | New trial registered | lixisenatide | iGlarLixi CGM Study in Chinese T2D Individuals After OADs | Recruiting, n=678 | P4 |
| 2026-08-21 | New trial registered | lixisenatide | Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus | Completed, n=542 | P2 |
| 2026-08-21 | New trial registered | lixisenatide | Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients | Completed, n=323 | P2 |
| 2026-08-21 | New trial registered | lixisenatide | Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents | Recruiting, n=1,316 | P4 |
| 2026-08-21 | New trial registered | lixisenatide | GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA) | Completed, n=311 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin | Completed, n=10 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients | Terminated, n=2 | P2 |
| 2026-08-21 | New trial registered | lixisenatide | GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin | Completed, n=484 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine | Completed, n=136 | P4 |
| 2026-08-21 | New trial registered | lixisenatide | Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi | Completed, n=161 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus | Completed, n=105 | P4 |
| 2026-08-21 | New trial registered | lixisenatide | Effect of LIXIsenatide on the Renal System | Completed, n=40 | P4 |
| 2026-08-21 | New trial registered | lixisenatide | Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin | Completed, n=447 | P3 |
| 2026-08-21 | New trial registered | lixisenatide | Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin | Completed, n=451 | P3 |
| 2026-08-21 | New trial registered | aleniglipron | Aleniglipron Phase 2 in Type 2 Diabetes MellitusNCT07400588 · Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Active, not recruiting, n=58 | P2 |
| 2026-08-21 | New trial registered | aleniglipron | Aleniglipron Phase 2 Body Composition StudyNCT07169942 · Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Active, not recruiting, n=71 | P2 |
| 2026-08-21 | New trial registered | aleniglipron | A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related ComorbidityNCT06693843 · Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Completed, n=230 | P2 |
| 2026-08-21 | New trial registered | aleniglipron | A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related ComorbidityNCT06703021 · Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Completed, n=85 | P2 |
| 2026-08-21 | New trial registered | olatorepatide | Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes | Recruiting, n=360 | P2 |
| 2026-08-21 | New trial registered | olatorepatide | Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US | Active, not recruiting, n=120 | P2 |
| 2026-08-21 | New trial registered | albiglutide | Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus | Completed, n=67 | P2 |
| 2026-08-21 | New trial registered | albiglutide | Dose Ranging Study of Albiglutide in Japanese Subjects | Completed, n=215 | P2 |
| 2026-08-21 | New trial registered | albiglutide | A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus | Withdrawn | P3 |
| 2026-08-21 | New trial registered | albiglutide | Safety and Efficacy Study of Albiglutide in Type 2 Diabetes | Completed, n=309 | P3 |
| 2026-08-21 | New trial registered | albiglutide | Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus | Completed, n=9,463 | P4 |
| 2026-08-21 | New trial registered | albiglutide | A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus | Completed, n=374 | P3 |
| 2026-08-21 | New trial registered | albiglutide | Albiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes | Completed, n=44 | P2 |
| 2026-08-21 | New trial registered | albiglutide | Safety and Efficacy of Albiglutide in Type 2 Diabetes | Completed, n=310 | P3 |
| 2026-08-21 | New trial registered | albiglutide | In-patient Study With GSK716155 In Patients With Type 2 Diabetes Mellitus | Completed, n=60 | P2 |
| 2026-08-21 | New trial registered | albiglutide | Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects | Terminated, n=8 | P4 |
| 2026-08-21 | New trial registered | albiglutide | Pharmacokinetics/Pharmacodynamics of Albiglutide | Completed, n=283 | P2 |
| 2026-08-21 | New trial registered | albiglutide | Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus | Completed, n=308 | P3 |
| 2026-08-21 | New trial registered | albiglutide | Albiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus | Withdrawn | P3 |
| 2026-08-21 | New trial registered | albiglutide | A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects | Completed, n=20 | P4 |